loading
Pds Biotechnology Corporation stock is traded at $1.08, with a volume of 484.44K. It is down -9.24% in the last 24 hours and down -18.80% over the past month. PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.19
Open:
$1.17
24h Volume:
484.44K
Relative Volume:
0.80
Market Cap:
$48.16M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-0.9231
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
-18.18%
1M Performance:
-18.80%
6M Performance:
-70.41%
1Y Performance:
-73.13%
1-Day Range:
Value
$1.08
$1.18
1-Week Range:
Value
$1.08
$1.339
52-Week Range:
Value
$1.08
$4.42

Pds Biotechnology Corporation Stock (PDSB) Company Profile

Name
Name
Pds Biotechnology Corporation
Name
Phone
800-208-3343
Name
Address
303A COLLEGE ROAD EAST, PRINCETON
Name
Employee
25
Name
Twitter
@pdsbiotech
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
PDSB's Discussions on Twitter

Compare PDSB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PDSB
Pds Biotechnology Corporation
1.08 48.16M 0 -40.56M -35.28M -1.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-01-22 Initiated B. Riley Securities Buy
Jun-28-21 Initiated Cantor Fitzgerald Overweight
Nov-10-20 Upgrade H.C. Wainwright Neutral → Buy
May-27-20 Initiated Alliance Global Partners Buy
Mar-09-20 Initiated Noble Capital Markets Outperform
Oct-24-19 Initiated Chardan Capital Markets Buy
View All

Pds Biotechnology Corporation Stock (PDSB) Latest News

pulisher
Mar 31, 2025

Virtu Financial LLC Takes $89,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN

Mar 31, 2025
pulisher
Mar 30, 2025

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish - Asianet Newsable

Mar 30, 2025
pulisher
Mar 29, 2025

HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts PDS Biotechnology stock target to $13 By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts PDS Biotechnology stock target to $13 - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

PDS Biotechnology Advances Cancer Immunotherapy Trials - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

PDS Biotech commences phase 3 trial for HPV cancer therapy By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

PDS Biotech commences phase 3 trial for HPV cancer therapy - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

PDS Biotech Advances Cancer Immunotherapy with New Clinical Trial - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

PDS Biotechnology Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

PDS BIOTECHNOLOGY Earnings Results: $PDSB Reports Quarterly Earnings - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update - MarketScreener

Mar 27, 2025
pulisher
Mar 26, 2025

A Look at PDS Biotechnology's Upcoming Earnings Report - Benzinga

Mar 26, 2025
pulisher
Mar 25, 2025

PDS Biotechnology Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference - TradingView

Mar 25, 2025
pulisher
Mar 23, 2025

PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey

Mar 23, 2025
pulisher
Mar 22, 2025

10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey

Mar 22, 2025
pulisher
Mar 19, 2025

PDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results - The Manila Times

Mar 18, 2025
pulisher
Mar 15, 2025

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Morningstar

Mar 14, 2025
pulisher
Mar 13, 2025

PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - The Manila Times

Mar 13, 2025
pulisher
Mar 11, 2025

PDS Biotech Leadership to Participate in March Conferences - The Manila Times

Mar 11, 2025
pulisher
Mar 10, 2025

PDS Biotechnology commences trial for head and neck squamous cell carcinoma - Yahoo

Mar 10, 2025
pulisher
Mar 10, 2025

H.C. Wainwright maintains $21 target on PDS Biotech stock By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

H.C. Wainwright maintains $21 target on PDS Biotech stock - Investing.com India

Mar 10, 2025
pulisher
Mar 09, 2025

HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

PDS Biotech begins phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia

Mar 08, 2025
pulisher
Mar 08, 2025

PDS Biotech launches phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia

Mar 08, 2025
pulisher
Mar 07, 2025

PDS Biotech launches phase 3 trial for HPV cancer therapy - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

PDS Biotech begins phase 3 trial for HPV cancer therapy - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer - The Manila Times

Mar 07, 2025
pulisher
Mar 06, 2025

Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors - The Globe and Mail

Mar 06, 2025
pulisher
Mar 04, 2025

Understanding the Risks of Investing in PDS Biotechnology Corporation (PDSB) - Knox Daily

Mar 04, 2025
pulisher
Mar 04, 2025

PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock By Investing.com - Investing.com Canada

Mar 04, 2025
pulisher
Mar 03, 2025

PDS Biotechnology director Gregory Freitag purchases $24,999 in stock By Investing.com - Investing.com Canada

Mar 03, 2025

Pds Biotechnology Corporation Stock (PDSB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Cap:     |  Volume (24h):